Premium
Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody
Author(s) -
Rose John W.,
Watt Hilary E.,
White Andrea T.,
Carlson Noel G.
Publication year - 2004
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20287
Subject(s) - daclizumab , medicine , multiple sclerosis , monoclonal antibody , ambulatory , interleukin 2 , monoclonal , cytokine , immunology , antibody
We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin‐2 receptor α chain, was safe and efficacious in relapsing–remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity. Ann Neurol 2004